Kinaset Therapeutics

Kinaset Therapeutics was formed to develop novel therapeutics for severe respiratory diseases. Kinaset’s lead program KN-002 is a novel pan-JAK inhibitor for the treatment of eosinophilic and non-eosinophilic severe asthma.

Headquarters Medfield, MA
Website www.kinasettherapeutics.com
Pipeline Status Phase 1-ready
Partners Vectura
Twitter @KinasetT
LinkedIn Kinaset Therapeutics​